Bipolar Disorder Therapeutics Market Report 2025

This Bipolar Disorder Therapeutics market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The bipolar disorder therapeutics market size has grown strongly in recent years. It will grow from $7.44 billion in 2024 to $7.89 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to rise in medical research and developments, increased healthcare expenditure, rise in prevalence of mental health disorders, rise in patient advocacy.

The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $9.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing prevalence of bipolar disorder, government initiatives, expansion of healthcare infrastructure, growing adoption of a sedentary lifestyle. Major trends in the forecast period include personalized treatment approaches, digital health integration, innovative medications, preventive interventions, neuroimaging and biomarkers.

The rising healthcare expenditure is projected to drive the growth of the bipolar disorder therapeutics market in the future. Healthcare infrastructure encompasses all expenses related to medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. Several factors contribute to the increase in healthcare spending, including an aging population, a surge in chronic diseases, and escalating drug costs, all of which significantly heighten the demand for medical services and treatments. As awareness of mental health issues grows, the diagnosis of bipolar disorder is also on the rise, resulting in greater demand for therapeutic interventions. For example, in November 2023, the Canadian Institute for Health Information, a non-profit organization based in Canada, projected that total health spending in Canada would increase by 2.8% in 2023, following a modest growth of just 1.5% in 2022. Thus, the increasing healthcare expenditure is fueling the growth of the bipolar disorder therapeutics market.

The growing demand for psychological counseling is expected to significantly contribute to the expansion of the bipolar disorder therapeutics market. Psychological counseling, a form of therapy aimed at improving mental health and enhancing overall quality of life, plays a crucial role in managing symptoms of bipolar disorder. Psychotherapy helps individuals identify triggers for bipolar episodes and equips them with coping mechanisms for stressors. According to The Centers for Disease Control and Prevention (CDC), from 2019 to 2021, there was an increase in the percentages of both men and women aged 18-44 in the U.S. who received any mental health treatment in the past 12 months. The surge in demand for psychological counseling underscores a critical aspect of bipolar disorder therapeutics, driving the market forward.

Strategic partnerships have become a prominent trend in the bipolar disorder therapeutics market. Major companies in this sector are increasingly focusing on collaborations to strengthen their market position. For example, in April 2022, BioXcel Therapeutics, Inc., a biopharmaceutical company based in the US, received FDA approval for IGALMITM (dexmedetomidine), a sublingual film designed for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. This film dissolves in the mouth and is specifically formulated to address mild, moderate, or severe agitation in these patient groups. The drug is engineered for rapid onset of action, allowing for effective management of agitation episodes.

Major companies in the Bipolar Disorder Therapeutics and related market are focusing on developing new treatments for depressive episodes linked to bipolar I or II disorder in order to reach larger customer bases, boost sales, and increase revenue. Among the various types of bipolar disorders, bipolar depression represents the most common and severe clinical manifestation. Compared to manic or hypomanic episodes, these depressive episodes are associated with a worse prognosis, longer duration, and more frequent recurrences. For example, in March 2024, the EDIT-B consortium, a collaborative organization based in France that specializes in innovative diagnostic tools and biomarkers, launched myEDIT-B, a novel blood diagnostic tool designed to provide objective biological data to assist psychiatrists and healthcare professionals in making accurate diagnoses. This tool analyzes RNA editing-based biomarkers and has demonstrated sensitivity and specificity rates exceeding 80%. By enabling faster and more precise diagnoses - potentially reducing wait times to within four weeks - myEDIT-B aims to address the significant issue of misdiagnosis in mental health, with approximately 40% of individuals diagnosed with depression possibly having bipolar disorder instead.

In June 2023, Brain Therapeutics, a Greece-based central nervous system specialty company, made a strategic move by acquiring the prescription drug brand Lazap (olanzapine) from the Greek pharmaceutical company Lyofin Ltd., the terms of which were undisclosed. This acquisition, facilitated by Brain Therapeutics, aims to broaden Neuraxpharm Group's therapeutic product portfolio in Greece and Europe. The agreement positions Neuraxpharm Group to leverage its expertise in the central nervous system (CNS) field, ensuring that Lazap reaches a wider audience. Lyofin Ltd., the Greek pharmaceutical company, is a key player in this collaboration, contributing to the expansion of Neuraxpharm Group's offerings in the CNS therapeutic domain. This strategic move reflects the industry's dedication to meeting healthcare demands by enhancing its product portfolio and geographical reach.

Major companies operating in the bipolar disorder therapeutics market include AbbVie Inc., Pfizer Inc., Astellas Pharma Inc, AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd, H. Lundbeck A/S, Janssen Pharmaceuticals, Sanofi S.A., Lundbeck A/S, Allergan plc, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Celon Pharma SA, NeuroRx Inc., IntraCellular Therapies Inc., Sumitomo Pharma Co. Ltd., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.

Bipolar disorder therapeutics consist of medications such as mood stabilizers, antidepressants, antipsychotics, and psychological counseling aimed at controlling symptoms associated with bipolar disorders. These therapeutics play a crucial role in the treatment and management of bipolar disorders.

The primary categories of drugs within bipolar disorder therapeutics include mood stabilizers, antipsychotic drugs, antidepressant drugs, and other medications. Mood stabilizers constitute a class of drugs specifically designed for the management and treatment of bipolar disorders. Various mechanisms are employed, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and others. These drugs are commonly available through hospital pharmacies, retail pharmacies, and online pharmacies.

The bipolar disorder therapeutics market research report is one of a series of new reports that provides bipolar disorder therapeutics market statistics, including bipolar disorder therapeutics industry global market size, regional shares, competitors with a bipolar disorder therapeutics market share, detailed bipolar disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder therapeutics industry. This bipolar disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the bipolar disorder therapeutics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bipolar disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bipolar disorder therapeutics market includes revenues earned by entities by family-focused therapy, interpersonal and social rhythm therapy, cognitive behavioral therapy and dialectical behavior therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.